Company intelligence / Profile preview

Boost Solutions

Ownership: Private
Development stage: Other

Overview

BOOST Pharma has developed BT-101, an allogeneic mesenchymal stem cell therapy for osteogenesis imperfecta. In preclinical models and early human studies, BT-101 demonstrated increased bone formation and safety. The Phase I/II BOOSTB4 trial showed positive results in children with OI Types III and IV, including improved growth curves and reduced fractures without adverse immune responses. The company is now preparing for a pivotal Phase III trial.

Therapeutic areas: Rare Diseases
Modalities: Cell therapyMesenchymal stem cell therapyBiologic
Industry: Biotech

Partnerships

Investors include Industrifonden and KD Capital as of May 2024Academic collaboration/funding from Karolinska InstitutetHorizon 2020 grantSwedish Research Council

Beyond the preview

Go deeper on Boost Solutions.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Boost Solutions.

Explore the full profile